Amphastar Pharmaceuticals earnings date
Amphastar Pharmaceuticals (29A) Q3 2026 Earnings Report
DE:29A Q3 2026 EPS Results
- Actual EPS
- EUR 1.02
- Consensus EPS
- EUR 0.77
- Beat/Miss
- Beat by +EUR 0.25
- One Year Ago EPS
- EUR 0.83
DE:29A Q3 2026 Revenue Results
- Actual Revenue
- EUR 185.88M
- Expected Revenue
- EUR 176.85M
- Beat/Miss
- Beat by +EUR 9.03M
- YoY Revenue Growth
- +8.22%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Amphastar Pharmaceuticals's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive, supported by record revenue, record BAQSIMI and Primatene MIST sales, improved net income and adjusted earnings, progress on pipeline programs, and additional shareholder-return authorization. These positives were tempered by lower gross margin, persistent BAQSIMI pricing pressure, declines in epinephrine and glucagon, and ongoing IMS remediation costs, release delays, and backlog. Overall, the highlights significantly outweighed the lowlights.
For the fourth quarter, management expects sales to increase in the high single-digit range compared to the fourth quarter of last year, incorporating a modest slowdown in IMS sales; IMS remediation expense was probably between $2 million and $3 million in the third quarter and will probably be a little bit higher than that in each of the next two or three quarters. Management is not prepared to give guidance for 2027, but expects strong growth from BAQSIMI, growth from Primatene MIST, and annualized sales of ipratropium bromide; it also expects lidocaine demand to continue into next year, API sales to continue around the same level, and strong teriparatide sales, although it may not get growth out of that. The insulin biosimilar is expected to launch next year, but there is no firm date, while AMP-018 is expected to have a limited opportunity due to the competitive nature of that environment and remains on track for the 2027 commercialization; the company’s goal is to file AMP-104 by the end of 2028.
- Record Quarterly RevenueThird-quarter revenue reached a record $207.6 million, increasing approximately 8% year-over-year from $191.8 million and 13% sequentially. Growth was driven primarily by BAQSIMI and Primatene MIST, supplemented by recently launched products.
- BAQSIMI Delivered Record SalesBAQSIMI generated record quarterly net sales of $58.8 million, up approximately 10% year-over-year from $53.6 million. Higher unit volumes contributed $7.4 million in sales, while measures to address duplicate 340B discounts continued to reduce their impact relative to the second quarter.
- Primatene MIST Continued to GrowPrimatene MIST sales increased approximately 9% year-over-year to $31.5 million from $28.8 million, driven by the second-quarter price increase and higher unit volumes. In-store unit sales increased approximately 2.5% year-over-year.
- Recently Launched Products Added Meaningful SalesIpratropium bromide, launched in April, generated $6.6 million in third-quarter sales, while teriparatide contributed $6.4 million. These launches supported portfolio growth and partially offset headwinds affecting certain established products.
- Lidocaine Sales Increased on Strong DemandLidocaine sales increased 29% to $16.6 million from $12.9 million, driven by higher demand associated with a shortage from another supplier. Management expects demand for the product to continue into next year.
- Other Pharmaceutical and API Sales IncreasedOther pharmaceutical product sales increased 9% to $70.2 million from $64.1 million, primarily due to teriparatide sales. API sales from the ANP subsidiary contributed $6.2 million and had a positive impact on sales.
- Net Income and Adjusted Earnings ImprovedThird-quarter net income increased to $37.8 million, or $0.87 per share, from $17.4 million, or $0.37 per share, in the prior-year period. Adjusted net income increased to $49.3 million, or $1.14 per share, from $44.7 million, or $0.93 per share.
- Operating Cash Flow and Share Repurchase AuthorizationThe company generated approximately $43.3 million in third-quarter cash flow from operations. The board also authorized an additional $50 million for the share buyback program.
- Lower General and Administrative ExpensesGeneral and administrative spending decreased 57% to $16.8 million from $39.5 million, primarily because the prior-year period included a legal settlement.
- Progress on IMS Remediation and Essential Medicine SupplyThe company continued implementing corrective actions following the FDA warning letter, worked closely with the FDA and a third-party partner, and maintained the supply of essential medicines, including products addressing ongoing drug shortages. Management said remediation work was progressing well and that additional quality resources had been added.
- Insulin Aspart Biosimilar Program AdvancedThe company remains on track to support a potential commercial launch of its insulin aspart biosimilar and interchangeable product in 2027, subject to FDA approval. Clinical, manufacturing, and commercialization preparations continued during the quarter.
- Broad Biosimilar and Complex Product Pipeline ProgressDevelopment activities continued across the broader biosimilar portfolio and additional complex inhalation and injectable candidates. The company also continued advancing AMP-101, AMP-109, AMP-110, and AMP-107 through clinical, non-clinical, formulation, manufacturing, and regulatory activities.
- Proprietary Primatene Development ProgramAMP-104, a new Primatene MIST formulation with lower global warming potential, has one approved patent and another patent application filed. The company is targeting a filing by the end of 2028 and said the program is intended to support long-term Primatene MIST brand protection and compliance with future propellant requirements.
- Fourth-Quarter Sales GuidanceManagement expects fourth-quarter sales to increase in the high single-digit range compared with the fourth quarter of the prior year, incorporating a modest slowdown in IMS sales while corrective actions are prioritized.
- Ipratropium Market Share Continued to GrowManagement expects ipratropium sales to continue increasing from the third-quarter level, citing continued prescription growth and market-share gains. Amphastar currently remains the only generic in that market.
- Commercial and Manufacturing Platform Remains a Strategic FoundationManagement highlighted its U.S.-based manufacturing footprint, vertically integrated operating model, and commercial portfolio as foundations for investing in manufacturing, development, and commercialization capabilities.
DE:29A Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.70- | 0.65 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 0.771.02 | 0.83 | 22.58% (+0.19) | |
| Aug 06, 2026 | 2026 (Q2) | 0.560.81 | 0.76 | 7.06% (+0.05) | |
| May 07, 2026 | 2026 (Q1) | 0.630.38 | 0.66 | -43.24% (-0.29) | |
| Feb 26, 2026 | 2025 (Q4) | 0.810.65 | 0.82 | -20.65% (-0.17) | |
| Nov 06, 2025 | 2025 (Q3) | 0.740.83 | 0.86 | -3.13% (-0.03) | |
| Aug 07, 2025 | 2025 (Q2) | 0.660.76 | 0.84 | -9.57% (-0.08) | |
| May 07, 2025 | 2025 (Q1) | 0.620.66 | 0.93 | -28.85% (-0.27) | |
| Feb 27, 2025 | 2024 (Q4) | 0.840.82 | 0.79 | 4.55% (+0.04) | |
| Nov 06, 2024 | 2024 (Q3) | 0.880.86 | 1.03 | -16.52% (-0.17) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
